In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA

• Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in…

Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x

• Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythemat…

🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946 SLE, birth control, & pregnancy planning 🔥30% of women used no birth control despite only 17% voicing interest in pregnancy 🔥More 1/2 of women interested in pregnancy were not medically ready #ACR22 @RheumNow

Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm

• Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflamma…

Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2

• Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarker…

Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr

• Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specific…

Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b

• Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Dam…

Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo

• Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among …

Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, significant increase in anxiety @RheumNow #ACR22 Abstr#0886 https://t.co/1a3sayBEnl https://t.co/jflc3UTbIh

• Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three…

Bui et al. Outcomes in Adult onset Stills Disease. >40% required ICU admission and 3.5% died in this retrospective study. No effect of concomittent pneumonia. @RheumNow #ACR22 Abstr#0829 https://t.co/YxkXJJ7EGR https://t.co/mMbQ14iRL1

• Adult Onset Still's Disease: A Retrospective Study of Objective Manifestat…

Madan et al. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 was associated with higher mortality in Macrophage Activation Syndrome @RheumNow #ACR22 Abstr#0825 https://t.co/jL58oCCEWa https://t.co/9V4PW49EyC

• Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective St…

Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Abstr#0884 https://t.co/z9oeKPLq5z https://t.co/YFkIBEqT0c

• Serum Calprotectin Can Differentiate Between Sustained Remission and Low Diseas…

Sarilumab in GC resistant PMR 🔥SAPHYR🔥 👉Arm 1- sar 200mg Q2W + 14wk GC 👉 Arm 2- PBO Q2W + 52wk GC 🌟RESULTS🌟 💪🏻 Arm 1 - PMR symp + signs ⬇️ wk 2 with continued improvement until wk 52 🌟Arm 1- ⬇️ chance flare post achieving remission #ACR22 @RheumNow https://t.co/tXQuuoAelP

CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx, and those with SCLE. Abs 0338 #ACR22 @RheumNow https://t.co/XxHjkNL5Hf https://t.co/1WtgmVM7Iz

• Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of In…

Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt

• Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616…